Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2023-07-19 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement dated July 19, 2023, from Jubilant Pharmova Limited regarding the outcome of a Board Meeting where the unaudited standalone and consolidated financial results for the quarter ended June 30, 2023, were approved. It includes a Limited Review Report by the statutory auditors on these unaudited financial results. The document contains actual financial data, including revenue, expenses, profit/loss, and earnings per share for the quarter, as well as notes on accounting standards and review procedures. The presence of comprehensive financial statements and auditor review indicates this is an Interim / Quarterly Report rather than a mere announcement or certification. The document is about quarterly financial results, not a full annual report or just an earnings release summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-07-19 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended June 30, 2023. It is addressed to stock exchanges and the company secretary, and it contains no financial statements or detailed financial data. The document is short (2501 characters) and serves as a regulatory compliance certificate rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and certification documents.
2023-07-11 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document contains multiple notices and advertisements related to tenders, property sales, and invitations for bids from various organizations and government bodies. There is no indication of financial statements, management discussion, earnings data, or regulatory certifications. The content is primarily announcements of public tenders and related procedural information. This type of content does not fit into financial reports, earnings releases, or management reports. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement and miscellaneous filing that does not fit other categories.
2023-07-02 English
Board Meeting — JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 19-Jul-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for…
Regulatory Filings
2023-06-27 English
Board Meeting — Other business matters
Board/Management Information Classification · 95% confidence The document is a short notice informing about a scheduled Board Meeting on July 19, 2023, to consider the unaudited financial results for the quarter ended June 30, 2023. It is an intimation or announcement of a future event rather than the financial results or report itself. The document references Regulation 29 of the SEBI Listing Regulations, which governs disclosures related to board meetings. The length is only 1103 characters, indicating it is a brief announcement. According to the rules, such notices about board meetings and financial results consideration fall under Board/Management Information (MANG). It is not the actual financial report or earnings release, nor a report publication announcement. Therefore, the correct classification is MANG with high confidence.
2023-06-27 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice dated June 23, 2023, addressed to stock exchanges regarding the closure of the trading window for designated persons due to upcoming financial results announcement for the quarter ending June 30, 2023. It is a compliance announcement related to insider trading regulations and does not contain any financial data, report, or detailed analysis. The document is brief (1199 characters) and serves as an informational regulatory filing to the stock exchanges. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance announcement rather than a financial report or other specific filing type.
2023-06-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.